For years, the ALSFRS has been the standard for tracking the disease progression of people living with ALS. But researchers are looking for less subjective methods.

The ALS Therapy Development Institute (ALS TDI) is proud to announce that it will lead all research operations for Champion Insights—a new study planned to launch this fall in partnership with Answer ALS and Augie’s Quest to Cure ALS. This effort aims to uncover critical genetic and metabolic factors that may help explain the significantly higher incidence of amyotrophic lateral sclerosis (ALS) among endurance athletes, military service members, and other potentially high-risk groups.

When exploring ALS trials and experimental treatments, people living with ALS and their families often encounter terms like Expanded Access Program (EAP), Open‑Label Extension (OLE), and Open‑Label Studies. While these sound similar, and all involve access to an investigational drug, each pathway serves a different purpose within clinical development.